Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx(TM) System for Chronic Bronchitis

First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life MENLO PARK, Calif., Sept. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala) today announced that its RheOx™ system has... Devices, Regulatory Gala Therapeutics, RheOx, Bronchial Rheoplasty, Chronic Bronchitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news